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Integrase strand transfer inhibitor (INSTI)-based antiretroviral 
therapy (ART) is first line for treatment of people with human 
immunodeficiency virus (PWH). Emerging data suggest the 
possibility of adverse metabolic effects of these medications. We 
describe 3 cases in which PWH developed hyperglycemia and 
ketoacidosis within months of being switched to bictegravir-
based ART.
Keywords:  bictegravir; diabetes; HIV; hyperglycemia; 
integrase strand transfer inhibitors.
People with human immunodeficiency virus (PWH) have in-
creased risk for developing type 2 diabetes mellitus (T2DM), 
regardless of exposure to antiretroviral therapy (ART) 
[1]. Although early ART regimens were associated with 
dyslipidemia and other metabolic derangements, contem-
porary ART, including the integrase strand transfer inhib-
itor (INSTI) class, are thought to have a better safety profile. 
Recent data has suggested that INSTI use may be associated 
with weight gain and the development of insulin-resistant 
diabetes [2, 3] and, in rarer cases, accelerated hypergly-
cemia [4–6]. Bictegravir (BIC) is a second-generation INSTI, 
available in coformulation with emtricitabine (FTC) and 
tenofovir alafenamide (TAF), and is currently recommended 
as a first-line ART regimen for newly diagnosed PWH [7, 8]. 
To our knowledge, there are no case reports of BIC-related 
accelerated hyperglycemia.
METHODS
We identified 3 PWH with new or acutely worsening hyper-
glycemia with ketoacidosis after initiation of BIC-based ART 
regimens.
Patient Consent Statement
The Washington University Institutional Review board evalu-
ated this project and deemed it nonhuman subject research.
Case 1
A 50-year-old Filipino male with a 25-year history of human 
immunodeficiency virus (HIV), chronic hepatitis B, and 
schizoaffective disorder presented off medications for 2 months. 
His ART was transitioned from rilpivirine (RPV)/tenofovir 
disoproxil fumerate (TDF)/FTC to BIC/TAF/FTC. His other 
medications included stable doses of sertraline, prazosin, and 
paliperidone palmitate; the latter he had received by intramus-
cular injection for the past 3 years. His HbA1c at the time of 
medication transition was 6.6% and he had a fasting glucose of 
85 mg/dL. Approximately 3 weeks after the ART switch, he had 
a random glucose of 223 mg/dL. Four months after the switch, 
he presented to the emergency department (ED) with abdom-
inal pain. He was found to have a blood glucose concentration 
greater than 400 mg/dL and an elevated blood ketone level of 
4.5 mmol/L. His C-peptide level was 1.2 ng/mL (normal limit 
1.1–4.4 ng/mL). Upon presentation to the hospital his HbA1c 
was >17%. He was discharged receiving 1.4 units of insulin/kg 
per day and his ART was transitioned back to RPV/TDF/FTC. 
Within 2 months of discharge, he had a 70% reduction in in-
sulin requirements with well controlled blood glucose concen-
trations and an HbA1c of 6.5%.
Case 2
A 56-year-old Black male with hypertension and well controlled 
HIV had his ART transitioned from efavirenz (EFV)/TDF/FTC 
to BIC/TAF/FTC based on insurance formulary. His other medi-
cation was a vitamin D supplement. Three weeks after the transi-
tion, he developed polyuria, polydipsia, and unintentional 15-kg 
weight loss. Laboratory evaluation in the ED revealed hypergly-
cemia (>500 mg/dL) and elevated blood ketones (4.4 mmol/L). 
His HbA1c on admission was 12.6%, which was increased 
from 6.0% 2 months prior. His insulin level on admission was 5 
mcIUnit/mL (normal limit 2.6 to 25 mcIUnit/mL) and C-peptide 
level was 2.2 ng/mL (normal limit 1.1–4.4 ng/mL). He required 
subcutaneous insulin at 0.6 units/kg per day. Four months after 
discharge, his insulin requirements decreased; however, his gly-
cemic control worsened, prompting an ART switch to RPV/TAF/
FTC. Eight months later his HbA1c was 7.2% on metformin only.
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Case 3
A 41-year-old Black male with well controlled HIV and chronic 
hepatitis B on abacavir (ABC)/lamivudine (3TC)/dolutegravir 
(DTG) and entecavir was transitioned to BIC/TAF/FTC and 
entecavir with plans to eventually be managed on BIC/TAF/
FTC only. His only other medications included valacyclovir 
and recently initiated methocarbamol and pregabalin, given 
for chronic pain. At the time of transition he had a fasting glu-
cose of 78 mg/dL. One month after transition he had a random 
glucose value of 157 mg/dL. Two months after the transition, 
he presented to the ED for nausea, vomiting, polyuria, and 
polydipsia. His blood glucose concentration was >600 mg/dL 
and blood ketones were 4.2 mmol/L. His C-peptide level was 
1.4 ng/mL (normal limit 1.1–4.4 ng/mL). His HbA1c had in-
creased to 12.4% compared with 5.6% from 3 months earlier. 
Insulin was initiated at a dose of 0.6 units/kg per day and ART 
was transitioned to FTC/TDF plus DTG. Two months after 
discharge, his blood glucose levels improved and his insulin 
requirement declined to 0.2 units/kg per day. Eight months 
after discharge his HbA1c was 5.0% and his insulin was being 
down-titrated.
DISCUSSION
We report 3 cases of individuals who transitioned ART to BIC/
FTC/TAF and developed diabetic ketoacidosis (DKA) within 
weeks to months after transition. Characteristics about the pa-
tients can be found in Table 1. To our knowledge, this is the 
first report of accelerated hyperglycemia associated with BIC-
based ART. None of the patients were receiving medications 
for diabetes previously and HbA1c values before starting BIC-
based ART were only modestly elevated (5.6%–6.6%). HbA1c 
at the time of presentation with hyperglycemia and ketoacidosis 
ranged from 12.4% to 17%. The short time period to develop-
ment of DKA and rapid worsening of HbA1c strongly impli-
cates the BIC as an associated factor. It is notable that no other 
medications affecting glycemia were changed or added before 
onset of dysglycemia. In addition, discontinuation of BIC-based 
ART resulted in significant decreases in insulin requirements at 
follow up.
There have been growing concerns of weight gain and long-
term cardiometabolic effects associated with INSTI-based ART 
[9–11]. Recent case reports have also documented the develop-
ment of accelerated hyperglycemia and DKA after initiation of 
these therapies. In One case series, 3 patients developed DKA 
while on DTG- or elvitegravir-based regimens [12]. However, 2 
of the 3 reported patients developed diabetes more than 1 year 
after starting an INSTI-based regimen, making the association 
with ART therapy less clear. Two other individual case reports 
have suggested a temporal association between initiation of the 
first-generation INSTI raltegravir and the development of DKA 
[5, 13]. Another reported case of DTG-associated hypergly-
cemia occurred after approximately 3 weeks of treatment in a 
patient who had prior history of well controlled type II diabetes 
[6]. More recently, DTG has been implicated in hyperglycemic 
Table 1. Characteristics of Patients who Developed Acute Hyperglycemia while on Bictegravir
Case 1 Case 2 Case 3
Age/Sex 50/Male 56/Male 41/Male
CD4+ T Cell count 345 792 114
HIV RNA at switch 17,900 copies/mL Undetectable <20 copies/mL
Previous ART regimen FTC/RPV/TDF EFV/FTC/TDF ABC/DTG/3TC
Reason for switch to B/F/TAF Represented after being off 
meds
Insurance formulary change Goal of monotherapy for HIV and 
HBV
Weight (kg) at time of switch 63.3 kg 100.9 kg 104.6 kg 
BMI at time of switch (kg/m2) 21.2 32.8 31.3
HBA1c at time of switch 6.6% 6% 5.6%
Time to onset of hyperglycemia presentation 4 months 3 weeks 2 months
Weight at presentation (kg) 54.4 Kg 84.4 kg 88.9 kg 
BMI at presentation (kg/m2) 18.3 28.3 26.6
HBA1c post ART switch 17% 12.6% 12.4%
Diabetic ketoacidosis present Yes Yes Yes
Initiating TAF Yes Yes Yes
C-peptide [NL 1.1–4.4] 1.2 2.2 1.4
GAD-65 or Insulin antibodies? No No No
Initial insulin requirement 2.5 units per kg daily 0.6 units per kg daily 0.6 units per kg daily
Regimen switched post hyperglycemic  
episode 
Yes Initially no, switched 6 months 
later
Yes
Regimen switched to post episode FTC/RPV/TDF RPV/TAF/FTC TDF/FTC + DTG
HBA1c at follow up (months) 6.5% (7) 7.2% (8)  5.0% (7)
Continued need for insulin at follow up? Yes; 0.4 units/kg No Yes; 0.2 units/kg
Abbreviations: ABC, abacavir; B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; BMI, body mass index; DTG, dolutegravir; ART, antiretroviral therapy; FTC, emtricitabine; HBV, hep-
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events in Uganda, at a rate of 0.47% [4]. An analysis of FDA 
Adverse Event Reporting Systems data has demonstrated re-
ported events of hyperglycemia related to BIC; however, the 
temporality and presence of DKA are unclear [14].
It is worth noting that in addition to BIC, all 3 cases initiated 
TAF. In patient 3, DTG was transitioned to BIC, which is a tran-
sition of one INSTI to another. This case could provide evidence 
of an association of hyperglycemia and TAF. Although cases of 
acute hyperglycemia have not been reported with TAF in other 
settings, it is possible that the observations presented may relate 
to the drug combination rather than an individual component 
of the regimen. However, in the Ugandan cohort, patients given 
DTG were not transitioned to TAF [4].
The mechanism leading to rapid acceleration of hypergly-
cemia in patients after initiation of INSTI-based ART is not 
clear. Although weight gain may play a role in development 
of T2DM, all of our patients lost weight between initiation of 
BIC and hospital presentation. All 3 PWH had modestly ele-
vated HbA1c values at baseline; however, they had rapid devel-
opment of severe hyperglycemia and ketoacidosis, suggesting 
that INSTI use may be associated with rapid acceleration of 
dysglycemia and that these agents may contribute to beta-cell 
dysfunction and/or insulin resistance independent of weight 
gain. The presence of ketoacidosis supports the possibility of 
impaired beta-cell function in addition to increased insulin re-
sistance. Although insulin requirements declined after a switch 
in ART, this can be seen after resolution of glucose toxicity and 
does not demonstrate that INSTIs directly impair beta-cell 
function. It is also not clear whether impaired glycemic con-
trol completely resolves with discontinuation of the offending 
INSTI. Future prospective studies will be necessary to clarify 
these mechanism(s).
The Department of Health and Human Services guidelines 
recommend close monitoring in the first 3  months after an 
ART switch. Patients should have a visit or phone call in the 
first couple weeks to assess possible side effects, and laboratories 
should be obtained in the first 2 months to assess for viral re-
bound [8]. It is unclear whether increased screening for diabetes 
after initiation of INSTI therapies is likely to improve outcomes, 
particularly given the rarity of these events. Educating patients, 
particularly those who have other risk factors for, or history of, 
diabetes, on signs of symptoms associated with new onset di-
abetes may be beneficial in early identification of postswitch 
metabolic changes.
CONCLUSIONS
These cases document the development of hyperglycemia and 
DKA shortly after BIC initiation. This may be an early signal 
of adverse metabolic effects of BIC because long-term studies 
are lacking. Bictegravir-containing ART is now first line for 
treatment of HIV in PWH and is likely to be prescribed with 
increasing frequency. Although it is not clear that routine 
screening for dysglycemia in patients after initiation of BIC is 
indicated, those with risk factors or history of diabetes should 
be alerted to signs and symptoms of hyperglycemia. Large 
population-level studies are needed to determine the overall 
risk and outcomes related to BIC use and its possible effect on 
metabolic conditions.
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